Literature DB >> 954813

A new probe for heterogeneity in muscarinic receptors: 2-methyl-spiro-(1, 3-dioxolane-4, 3')-quinuclidine.

A Fisher, M Weinstock, S Gitter, S Cohen.   

Abstract

The title compound (MSDQ) is a new muscarinic agonist related to 3-acetoxyquinuclidine (3-AcQ) but also of a highly rigid structure. In view of this, it may constitute a probe for the detection of heterogeneity among muscarinic receptors. Indeed, equipotent molar ratios (EPMR) for ACh, 3-AcQ and MSDQ were as follows: guinea pig ileum, 1 : 14 : 240; vasodepressor effect in the cat, 1 : 6 : 188. But EPMR for 3-AcQ and MSDQ as stimulants of the superior cervical ganglion in the cat were 1 : 1 and for the induction of tremors in mice, 9 : 5. No such subtle differences in receptor specificity were detected when the probe used was the 2, 2-diphenyl analogue (DiPSDQ) of MSDQ which was a powerful competitive antagonist in all systems, more potent than atropine, but with a CNS/PNS activity of 1.1 compared to 26 for atropine. In view of this, the use of potent antagonists as probes for muscarinic receptor heterogeneity is questionable.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 954813     DOI: 10.1016/0014-2999(76)90041-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

1.  Relative affinities of drugs acting at cholinoceptors in displacing agonist and antagonist radioligands: the NMS/Oxo-M ratio as an index of efficacy at cortical muscarinic receptors.

Authors:  S B Freedman; E A Harley; L L Iversen
Journal:  Br J Pharmacol       Date:  1988-02       Impact factor: 8.739

2.  Offset rate of action of muscarinic antagonists depends on their structural flexibility.

Authors:  Y Lass; S Akselrod; B Gavish; S Cohen; A Fisher
Journal:  Experientia       Date:  1979-05-15

3.  Comparison of the antimuscarinic activity of mianserin and amitriptyline in the cat superior cervical ganglion.

Authors:  Y H Kwok; F Mitchelson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-04       Impact factor: 3.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.